Ermium Therapeutics

Ermium Therapeutics is a biotechnology company primarily focused on developing innovative therapies for autoimmune diseases, based on a groundbreaking discovery that CXCR4 is a key regulator of inflammation. It is also responsible for research on systemic lupus erythematosus, dermatomyositis, Sjögren's syndrome, monogenic interferonopathies, and other conditions. Ermium Therapeutics is developing orally available drug candidates that can effectively control type 1 interferon.